Literature DB >> 12049482

The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables.

H M Dodds1, J Hanrahan, L R Rivory.   

Abstract

Irinotecan (CPT-11), a water-soluble and semi-synthetic topoisomerase I poison of the camptothecin family, has activity against both adult and paediatric malignancies. Recently, we demonstrated that CPT-11 (lactone) is also a potent inhibitor of human acetylcholinesterase (AChE) at clinically relevant concentrations. Attachment of heterocyclic and branched amino groups onto the camptothecin back-bone continues to be a strategy for the synthesis of water-soluble analogues, but this may lead to undesirable inhibition of AChE. In this study, we screened a range of camptothecin analogues, degradation products and metabolites for their ability to inhibit AChE. Those compounds possessing N-substitutions at C-10 were all found to inhibit AChE in a similar kinetic manner to CPT-11, but with a broad range of potencies. It is recognized that the charge-state is important for ligands that bind to the peripheral anionic site and we postulated that the protonated distal piperidine of CPT-11 would be important. To address this question, an N-methyl piperidinium iodide analogue was synthesized and tested. This derivative inhibited electric eel AChE with an inhibition constant (Ki) of 1 nM. Kinetic and deacylation experiments demonstrated that it acted relatively less as an inhibitor of deacylation than CPT-11. Overall, our experiments reveal that nitrogenous substitutions at the permissive C-10 of the camptothecin backbone may lead to AchE inhibition, particularly if they involve a quaternary nitrogen.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12049482

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  3 in total

1.  Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.

Authors:  Amita Patnaik; Kyriakos P Papadopoulos; Anthony W Tolcher; Muralidhar Beeram; Saïk Urien; Larry J Schaaf; Sanaa Tahiri; Tanios Bekaii-Saab; François M Lokiec; Keyvan Rezaï; Aby Buchbinder
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-30       Impact factor: 3.333

2.  Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.

Authors:  D Alan Anthoney; Jay Naik; Iain R J Macpherson; Donna Crawford; John M Hartley; Janet A Hartley; Tomohisa Saito; Masaichi Abe; Keith Jones; Masanori Miwa; Christopher Twelves; T R J Evans
Journal:  BMC Cancer       Date:  2012-11-21       Impact factor: 4.430

3.  Mechanisms of toxicity of 3-alkylpyridinium polymers from marine sponge Reniera sarai.

Authors:  Tom Turk; Robert Frangez; Kristina Sepcić
Journal:  Mar Drugs       Date:  2007-11-13       Impact factor: 5.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.